Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
mRNA
Biotech
Moderna scraps congenital virus program after vax fails ph. 3
While the mRNA-1647 vaccine was well-tolerated, Moderna said, the shot’s ability to prevent infection was well below the company’s target.
Darren Incorvaia
Oct 22, 2025 5:15pm
Arcturus' stock halves on cystic fibrosis readout
Oct 22, 2025 1:01pm
Moderna posts melanoma data behind decision to say 'I do' to IDO
Oct 13, 2025 5:15am
ARPA-H invests in Kernal's mRNA cell therapy
Oct 7, 2025 3:20pm
Ionis rare disease candidate ekes out phase 3 win
Sep 22, 2025 10:46am
Japan biotech inks RNA research pact that includes mRNA compounds
Sep 19, 2025 10:49am